ASSEMBLY, No. 5789
STATE OF NEW JERSEY
222nd LEGISLATURE
INTRODUCED NOVEMBER 16, 2026
Sponsored by:
Assemblywoman MARGIE DONLON, M.D.
District 11 (Monmouth)
SYNOPSIS
Prohibits denial of health benefits coverage for prescription drugs based on accelerated FDA approval.
CURRENT VERSION OF TEXT
As introduced.
An Act concerning health benefits coverage of certain prescription drugs and supplementing P.L.1997, c.192 (C.26:2S-1 et seq.).
Be It Enacted by the Senate and General Assembly of the State of New Jersey:
1. a. A carrier that offers a health benefits plan in this State which provides coverage for pharmacy services, prescription drugs, or participation in a prescription drug plan shall not exclude, restrict, or delay coverage of a prescription drug on the basis that the drug was approved by the federal Food and Drug Administration through the accelerated approval pathway pursuant to subsection (c) of section 506 of the “Federal Food, Drug, and Cosmetic Act” (21 U.S.C. s.356), which prohibited exclusion, restriction, or delay by a carrier includes, but shall not be limited to, making a medical necessity determination based on the drug’s approval through the accelerated approval pathway.
b. As used in this section, "carrier" means an insurance company, health service corporation, hospital service corporation, medical service corporation, or health maintenance organization authorized to issue health benefits plans in this State, and shall include the State Health Benefits Program and the School Employees' Health Benefits Program.
2. This act shall take effect on the 120th day following enactment and shall apply to contracts entered into or renewed after that date.
STATEMENT
This bill prohibits health insurance carriers (insurance companies, health, hospital, and medical service corporations, health maintenance organizations, and State and School Employees' Health Benefits Program contracts) from denying health benefits coverage for a prescription drug on the basis that the drug received accelerated federal Food and Drug Administration approval.
Specifically, a carrier is not to exclude, restrict, or delay coverage of a prescription drug on the basis that the drug was approved by the federal Food and Drug Administration through the accelerated approval pathway, which includes, but is not limited to, making a medical necessity determination based on the drug’s approval through the accelerated approval pathway.